### International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 03 Issue 06 June 2023

Page No: 1090-1094

DOI: https://doi.org/10.47191/ijmscrs/v3-i6-10, Impact Factor: 6.597

### A Review on Hepatotoxic Effects of Methotrexate Therapy with Possible Strategies that May Counteract Hepatotoxicity

#### Mohammed J Manna<sup>1</sup>, Murtadha S Jabur<sup>2</sup>, Atheer S. Alsabah<sup>3</sup>, Luma Saad Baqir<sup>4</sup>

<sup>1,4</sup>College of Dentistry, Mustansiriyah University, Iraq
<sup>2</sup>College of Pharmacy, National University for Science and Technology, Iraq.
<sup>3</sup>College of Pharmacy, Al-Bayan University, Iraq.

#### ABSTRACT

Methotrexate, inhibitor of a dihydrofolate reductase, is a chemotherapeutic treatment applied in many kinds of tumors as an anti-metabolite. also, Methotrexate applied to treat different other disorders, including diseases of autoimmunity, such as psoriasis, rheumatism, vasculitis and ulcerative colitis and Crohn's disease. However, Methotrexate induces toxic effects on neurons, kidney toxicity, and liver damage, also Methotrexate have been associated with elevation risk of hepatic injury, fibrosis and cirrhosis. Methotrexate work as a dihydrofolic acid analog that binds to the dihydrofolate reductase enzyme that prevent the synthesis of tetrahydrofolic acid, that is essential synthesis of DNA. Although folic acid combine with Methotrexate therapy to prevent hepatotoxic effects, folic acid may reduce therapeutic effects of Methotrexate so recent research focus incorporation of new agent to counteract Methotrexate induced hepatotoxicity that include vitamin B12, vitamin E, N-acetylcysteine, melatonin, Erdosteine, inulin, Ferulic acid, Human placental extract, Natural plant extract (flavonoids). These agents are promising to counteract Methotrexate induced hepatotoxicity.

**Materials and methods:** A comprehensive literature review on different published articles hepatotoxic effects of methotrexate and was carried out by electronic research on Medline, PubMed, Google scholar, and Cochrane Libran data bases using different searching terms related to prevention of methotrexate induced hepatotoxicity. The article focusses on clinical studies in different regions in the period of 2018-2022.

**Objective:** To search for new update modality preventive therapy for methotrexate induced liver damage Results: Recent study oriented for the prevention and treatment of methotrexate associated with hepatotoxicity.

**KEYWORDS:** Methotrexate induced hepatotoxicity, antioxidant.

#### INTRODUCTION

Methotrexate inhibitor for dihydrofolate reductase, is an antimetabolite applied as a chemotherapy for many kinds of tumors <sup>1</sup>. Methotrexate involved in treatment of other disease involving diseases of autoimmunity, like psoriasis, rheumatism, vasculitis and ulcerative colitis and Crohn's disease <sup>(2-5)</sup>. However, Methotrexate may cause neurotoxicity <sup>6</sup>, nephrotoxicity <sup>7</sup>, and hepatotoxicity <sup>(8,9)</sup>, Methotrexate have been linked to increase risk of liver damage, fibrosis and cirrhotic damage. Methotrexate work as a dihydrofolate analog which binds to the dihydrofolate reductase enzyme by preventing the production of tetrahydrofolic acid, that essential for production of DNA.

Many factors that may increase risk of methotrexate induced hepatotoxicity, involving alcohol consumption, aging, timing

for doses with Methotrexate and its amount of drug consumed by patient, medical history for liver disease, obesity, diabetic desease, hepatitis B or C virus infection and taking medicine associated with liver injury 8. Moreover, non-alcoholic fatty injury, were liver steatosis is detected without heavy alcohol consumption<sup>10</sup> which has been similarly associated with Methotrexate therapy <sup>11</sup>. As dangerous adverse effects also low doses, Methotrexate may cause liver fibrotic damage and even cirrhosis. Minimum Methotrexate doses in chronic plaque psoriatic lesion was detected to have a 7% increase risk for development of cirrhotic liver injury, and aminotransferase rises up to triple times than standard level that found in 8% of the patients examined <sup>13</sup>. The incidence of Methotrexate -induced hepatic fibrosis and cirrhosis 14.

#### ARTICLE DETAILS

#### Published On: 13 June 2023

Available on: https://ijmscr.org/

#### 1. Vitamin B12

This Vitamin is an vital vitamin that possess essential function in numerous activities in the human organ, involving DNA methylation and DNA biosynthesis, production of erythrocytes, with neuronal function<sup>15</sup>. Vitamin B12 belong to cobalamins compounds, mainly stored in the hepatic tissue, many studies have shown that vitaminB12 protect against numerous liver diseases such as acute hepatitis, cirrhosis<sup>16</sup>. Derya *et al* investigate the protective activity of vitamin B12 on the necrosis induced by methotrexate, a antagonist for folic acid. Vit B12 showed supplied experimental group appear improvement in all of the negative laboratory liver enzyme and histological finding. Therefore, Vitamin B12 is an essential supplement that applied for necrosis in tissue after methotrexate hepatotoxicity<sup>17</sup>.

#### 2. Vitamin E:

is a type of lipid-soluble vitamin, and found as eight different forms, were tocopherol is the main active form . vitamin E is very important physiological antioxidant, tocopherol also proposed to have the main cellular binding antioxidant utilized via human tissue<sup>18</sup>. Vitamin E consider the main protection to prevent peroxidation of cellular membrane that essential for the cellular immunity. Vitamin E has been approved to reduce and mange hepatic inflammatory tissue fibrosis through modulating response and inflammation and signaling cascade by reducing the production of interleukin-6, tumor growth factor-\beta1, tumor necrosis factor- $\alpha$ , and further inflammation cytokines<sup>19</sup>. On other hand Binit et al show in his study prophylactic doses with vitamin E had preventive potential against hepatotoxicity induced by methotrexate in this experimental research showed that vitE in combination with folic acid superior to folic acid alone therefore the study results seem to be effective in ameliorating the hepatotoxicity of methotrexate therefore assists to fix the therapeutic dosing in patients<sup>20</sup>.

#### 3. N-acetylcysteine:

is a classical antioxidant, usually included in experimental research and a celluar protective agent which effective for drug-induced hepatotoxicity. In the lab study, displayed that N-acetylcysteine maintain the hepatocyte from oxidation by preventing the production of peroxide free radical. N-acetylcysteine may also display its antioxidant effects on hepatocytes by preventing expression of adhesive materials, decreasing inflammatory cytokines and reduction-oxidation system inside cellular cytoplasm. However, Tuba *et al* reveal in his study that there is a valuable preventive effect of N-acetylcysteine against methotrexate-induced hepatic damage. The ameliorated action of N-acetylcysteine based on its potency to improve antioxidant cellular mechanism, and its capability to decrease inflammatory and apoptotic molecular cascade<sup>21</sup>.

#### 3-Melatonin (N-acetyl-5-methoxytryptamine):

Ayat *et al* <sup>22</sup> concluded in her study that melatonin is promising in the protecting liver tissue from methotrexate toxic effect by their radical scavenging activities and antioxidant<sup>22</sup>. Melatonin is produced mainly through the pineal gland and is suggested to have antioxidant and defensive potential in opposit to oxidative stress<sup>23</sup>. It has potent antioxidant action thus safing cellular tissue against oxidative stress of DNA molecule, proteins, and lipids that involved in disease pathogenic pathway<sup>24,25</sup>. Melatonin maintains the hepatocyte from oxidative stress induced by pathological hypoxia formation<sup>26</sup>. Since melatonin has potent antioxidative potential, therefore melatonin has the ability to prevent the patients against MTX induced hepatotoxicity.

**4. Erdosteine:** is a mucolytic agent that applied for the management of subacute lung disorder to improve bronchial clearance<sup>27</sup>. currently, a many experimental studies has emphasized the antioxidant potential of erdosteine, also to its approved mucolytic action <sup>28</sup>. however, erdosteine prevent oxidative tissue damage in many laboratory models studies that induced tissue damage by injecting animal with hepatotoxic drug<sup>29</sup>. study finding display that use of erdosteine in animal result improvement in liver damage by oxidation , inflammation, programed cell death, and pathological change, in comparison with methotrexate treated animal<sup>30</sup>.

**5. Inulin** (**IN**): a plant fructan-type polysaccharide, is commonly present naturally. The main wild sources of Inulin involve dahlia, chicory. Studies have establish that Inulin broad spectrum of biological activities, e.g. as a probiotic to enhance the intestinal flora environment, controlling glucose level, controlling cholesterol profile, antioxidant, antitumor, immunomodulatory action and new study show that Inulin with antioxidant action has hepatoprotective effects that mediated by the regulation of apoptosis and oxidative damage<sup>31</sup>.

**6. Ferulic acid:** as a polyphenolic drug, is produced through tyrosine and phenylalanine metabolic pathway and is mainly present in rice, barely, wheat, banana, tomato, citrus fruits and vegetables<sup>32</sup>. Ferulic acid established to be a potent cellular protective against oxidative stress, also effective for dermatological malignancy, viral infection, atrophy of muscular tissues, and fatigue<sup>33</sup>.On other hand Ferulic acid show many therapeutic actions, including anti-nociceptive, anti-inflammatory, anti-tumor, hypoglycemic, hypolipidemic, neuroprotection and hypotensive action<sup>34</sup>. Ferulic acid, possess polyphenolic nucleus with long side chain , which produce stabilization against phenoxy radicals, that are function

that are function as free radical scavenger ability<sup>35</sup>. However, Mozhdeh R *et al* found Ferulic acid in 100 mg/kg dose could can reduce oxidative damage, inflammatory response and enhance the internal cellular defense against oxidation by

methotrexate. So Ferulic acid would be a good treatment to inhibit methotrexate associated hepatotoxicity <sup>36</sup>.

#### 7. Human Placental Extract:

It has approved that maternal placental supply is the major of a huge number of biological effective growth organ factors<sup>37</sup>.like transforming growth factor-a (TGF-a) <sup>38</sup>, hepatocyte growth factor (HGF) and epidermal growth factor (EGF) <sup>39</sup>. Human placental extract also has Tryptophan as a major antioxidant content<sup>40</sup>. also, Human placental extract applied for numerous useful pharmacological indications, involving healing of wound <sup>40</sup>. Human placental extract was mentioned to improve hepatic regeneration after induction liver injury <sup>41</sup>and to inflammatory damage with apoptotic damage<sup>42</sup>. Mamdooh G approved in his study that Human placental extract will prevent methyotrexate induced hepatotoxicity in animals. Human placental extract show ability to improve and protect liver tissue against hepatotoxic agent by enhancing

The endogenous antioxidant liver markers with reduction lipid peroxidation, with anti-inflammatory action.

#### 8. Natural plant extract (flavonoids):

Include (Apigenin, Zingerone, Silibinin, Ellagic acid, Naringin) all of them are extract from natural plant, and approved by experimental studies to prevent and attenuate methotrexate induced hepatic injury by antioxidant, antiinflammatory and free radical scavenging properties<sup>(44,45,46,47,48)</sup>.

#### REFERENCES

- I. Ayad MW, El Naggar AA, El Naggar M. MTHFR C677T polymorphism: association with lymphoid neoplasm and effect on methotrexate therapy. *Eur J Haematol*. 2014;93:63–69. doi: 10.1111/ejh.12302.
- II. Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. *Lupus*. 2014;23:225–235. doi: 10.1177/0961203313519159.
- III. Roenigk HH, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 1998;38:478–485. doi: 10.1016/S0190-9622(98)70508-0.
- IV. Fournier MR, et al. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gastroenterol. 2010;105:1620–1626. doi: 10.1038/ajg.2010.21.
- V. Xu P, et al. The efficacy and safety of methotrexate in refractory Crohn's disease. *Zhonghua Nei Ke Za Zhi.* 2014;53:188–192.
- VI. Buizer AI, et al. Behavioral and educational limitations after chemotherapy for childhood acute lymphoblasticleukemiaorWilmstumor. *Cancer.* 200 6;106:2067–2075. doi: 10.1002/cncr.21820.

- VII. Abd El-Twab SM, et al. 18 β-Glycyrrhetinic acid protects against methotrexate-induced kidney injury by up-regulating the Nrf2/ARE/HO-1 pathway and endogenous antioxidants. *Ren Fail.* 2016;38:1516– 1527. doi: 10.1080/0886022X.2016.1216722.
- VIII. Mahmoud AM, et al. Methotrexate hepatotoxicity is associated with oxidative stress, and down-regulation of PPARγ and Nrf2: protective effect of 18β-glycyrrhetinic acid. *Chem Biol Interact.* 2017;270:59–72. doi: 10.1016/j.cbi.2017.04.009.
  - IX. .methotrexate-induced liver injury. *J Gastroenterol Hepatol.* 2001;16:1395–1401. doi: 10.1046/j.1440-1746.2001.02644.x.
  - X. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. *Arthritis Rheum.* 1992;35:1117–1125. doi: 10.1002/art.1780351003.
  - XI. Rau R, Karger T, Herborn G, Frenzel H. Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate. J Rheumatol. 1989;16:489–493.
- XII. Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. *Postgrad Med J.* 2006;82:315– 322. doi: 10.1136/pgmj.2005.042200.
- XIII. Walker TM, Rhodes PC, Westmoreland C. The differential cytotoxicity of methotrexate in rat hepatocyte monolayer and spheroid cultures. *Toxicol In Vitro*. 2000; 14:475–485. doi: 10.1016/S0887-2333(00)00036-9.
- XIV. Yeo CM, Chong VH, Earnest A, Yang WL. Prevalence and risk factors of methotrexate hepatoxicity in Asian patients with psoriasis. *World J Hepatol.* 2013;5(5):275. doi: 10.4254/wjh.v5.i5.275
- XV. Allen LH, Miller JW, de Groot L, Rosenberg IH, Smith AD, Refsum H, et al. Biomarkers of Nutrition for Development (BOND): vitamin B-12 review. J Nutr. 2018;148(suppl\_4):1995S–2027S.
- Mechie N.C., Goralzcyk A.D., Reinhardt L., Mihm S., Amanzada A., Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study. BMC Res Notes. 2015; 8 (1): 260.
- XVII. Derya Karabulut, Emel Ozturk, Nurhan Kuloglu, Ali Tuğrul Akin, Emin Kaymak & Birkan Yakan . Effects of vitamin B12 on methotrexate hepatotoxicity: evaluation of receptor-interacting protein (RIP) kinase. Naunyn-Schmiedeberg's Archivesof Pharmacology volume 393, pages2473– 2480 (2020).

- XVIII. S. Nemmiche, D. Chabane-Sari, P. Guiraud. Role of alpha-tocopherol in cadmium-induced oxidative stress in Wistar rat's blood, liver and brain. Chem. Biol. Interact., 170 (3) (2007), pp. 221-230.
- XIX. Shahramian I et al. Accelerating Effects of Vitamin E Supplementation on Liver Enzyme Normalization in Children with Acute Hepatitis A Infection; a Single-Blinded Clinical Trial. Archives of Clinical Infectious Diseases.2020;15:(6) e100591
- Binit Vaidya, Manisha Bhochhibhoya, and Shweta Nakarmi. Efficacy of Vitamin E in Methotrexate-Induced Hepatotoxicity in Rheumatoid Arthritis: An Open-Label Case-Control Study. Int J Rheumatol. 2020 1. doi: 10.1155/2020/5723485; 2020: 5723485.
- XXI. Tuba Demirci, Semin Gedikli, Nurinnisa Ozturk, Nevra Aydemir Celep. The Protective Effect of Nacetylcysteine Against Methotrexate-Induced Hepatotoxicity in Rat. EJMI 2019;3(3):219–226.
- XXII. Ayat O.S.Montasser, HananSaleh, Omar A.Ahmed-Farid, AidaSaad and Mohamed-Assem S.Marie. Protective effects of *Balanites aegyptiaca* extract, Melatonin and Ursodeoxycholic acid against hepatotoxicity induced by Methotrexate in male rats. Asian Pacific Journal of Tropical Medicine. Volume 10, Issue 6, June 2018; 10: 557-565.
- XXIII. R.J. Reiter. Interactions of the pineal hormone melatonin with oxygen-centered free radicals: a brief review. Braz Med Biol Res, 26 (11) (1993), pp. 1141-1155
- XXIV. M.A. Eghbal, A. Eftekhari, E. Ahmadian, Y. Azar mi, A. Parvizpur. A Review of Biological and Pharmacological Actions of Melatonin: Oxidant and Pro-oxidant Properties. J Pharma Reports, 1 (1) (2016), pp. 1-9
- XXV. K.A. Marshall, R.J. Reiter, B. Poeggeler, O.I. Aruo ma, B. Halliwell. Evaluation of the antioxidant activity of melatonin in vitro Free Radical Biol Med, 21 (3) (1996), pp. 307-315
- XXVI. E. Sewerynek, R.J. Reiter, D. Melchiorri, G.G. Orti z, A. Lewinski. Oxidative damage in the liver induced by ischemia-reperfusion: protection by melatonin Hepatogastroenterology, 43 (10) (1996), pp. 898-905
- XXVII. Saritas A, Kandis H, Baltaci D, Yildirim U, Kaya H, Karakus A, Colakoglu S, Memisogullari R, Kara IH. Nacetyl cysteine and erdosteine treatment in acetaminophen-induced liver damage. Toxicol Ind Health 2014; 30(7): 670-678.
- XXVIII. Akbulut S. Cytoprotective effects of amifostine, ascorbic acid and n-acetylcysteine against methotrexate-induced hepatotoxicity in rats. World J Gastroenterol 2014; 20(29): 10158-10165.

- XXIX. 29. Helvaci R, Koc A, Kozlu T, Kaya H, Sogüt S.
   Effects of erdosteine on acetaminophen-induced hepatotoxicity in rats. Toxicol Pathol 2008; 36(5): 714-719.
- XXX. Osama Abdelaziz Hassan, Entesar Farghally Amin, Rabab Ahmed Moussa. Protective effect of erdosteine against methotrexateinduced hepatotoxicity in rats. Tropical Journal of Pharmaceutical Research July 2020; 19 (7): 1465-1471.
- XXXI. 26Heibatullah Kalantar ,Nooshin Asadmasjedi,Mohammad rezaAbyaz MasoudMahdavinia,Narges Mohammad. Protective effect of inulin on methotrexate- induced liver toxicity in mice. Biomedicine & Pharmacotherapy February 2019;110: 943-950.
- XXXII. .Graf E. Antioxidant potential of ferulic acid. *Free Radic Biol Med.* 1992;13(4):435–448. doi:10.1016/0891-5849(92)90184-I
- XXXIII. Deuster P, Maier S, Moore V, Paton J, Simmons R, Vawter K. Dietary Supplements and Military Divers: A Synopsis for Undersea Medical Officers. Uniformed Services Univ of The Health Sciences Bethesda Md Dept Of Military; 2004.
- XXXIV. Ronchetti D, Borghi V, Gaitan G, Herrero JF, Impagnatiello F. NCX 2057, a novel NO-releasing derivative of ferulic acid, suppresses inflammatory and nociceptive responses in in vitro and in vivo models. Br J Pharmacol. 2009;158(2):569–579. doi:10.1111/j.1476-5381.2009.00324.x.
- XXXV. .Zhao Z, Moghadasian MH. Chemistry, natural sources, dietary intake and pharmacokinetic properties of ferulic acid: a review. *Food Chem*. 2008;109(4):691–702. doi:10.1016/j.foodchem.2008.02.039.
- XXXVI. Uehara Y, Kitamura N . Hepatocyte growth factor/scatter factor and the placenta. Placenta.1996; 17:97–101.
- XXXVII. Saito S, Sakakura S, Enomoto M, Ichijo M, Matsumoto K, Nakamura T. Hepatocyte growth factor promotes the growth of cytotrophoblasts by the paracrine mechanism. J Biochem.1995; 117:671–676.
- XXXVIII. Hofmann GE, Scott RT Jr, Bergh PA, Deligdisch L. Immunohistochemical localization of epidermal growth factor in human endometrium, decidua, and placenta. J Clin Endocrinol Metab.1991; 73:882– 887.
  - XXXIX. Lysiak JJ, Han VKM, Lala PK. Localization of transforming growth factor in the human placenta and decidua: role in trophoblast growth. Biol Reprod.1993; 49:885–894.

- XL. Watanabe S et al.L-tryptophan as an antioxidant in human placenta extract. J Nutr Sci Vitaminol.2002; 48:36–39
- XLI. Jung J et al.Epigenetic alterations of IL-6/STAT3 signaling by placental stem cells promote hepatic regeneration in a rat model with CCl4-induced liver injury. Int J Stem Cellsw.2015; 8:79–89.
- XLII. Chatterjee P *et al.* Human placenta-derived stromal cells decrease inflammation, placental injury and blood pressure in hypertensive pregnant mice. Clin Sci (Lond).2016; *130*:513–523.
- XLIII. Mamdooh G ,Mohamed S.A. Human placental extract ameliorates methotrexate-induced hepatotoxicity in rats via regulating antioxidative and anti-inflammatory responses. *Cancer Chemotherapy and* Pharmacology.2021; 88: 961–971.
- XLIV. F Sahindokuyucu-Kocasari, Y Akyol, and S Garli. Apigenin alleviates methotrexate-induced liver and kidney injury in mice. Human and Experimental Toxicology.2021;40:1721-1731.
- XLV. Goudarzi M, Basir Z, Malayeri A, Nesari A and Zaeemzadeh N. Zingerone Attenuates Methotrexate-Induced Hepatotoxicity in Rats. Jundishapur J Nat Pharm Prod. 2022; 17(3): e118745.
- XLVI. Yanaşoğlu E *et al.* Silibinin Effect on Methotrexate-Induced Hepatotoxicity in Rats. Eurasian J Med 2022; 54: 264-269.
- XLVII. Ebrahimi R, Reza Sepand M, Afshin Seyednejad S, Omidi A, Akbariani M, Gholami M, and Sabzevari O. Ellagic acid reduces methotrexate-induced apoptosis and mitochondrial dysfunction via up-regulating Nrf2 expression and inhibiting the IκBα/NFκB in rats. DARU Journal of Pharmaceutical Science. 2019; 27(2): 721–733.
- XLVIII. Elsawy H, Algefare A, Alfwuaires M, Khalil M, Omar M. Elmenshawy, Sedky A, and Abdel-Moneim A. Naringin alleviates methotrexate-induced liver injury in male albino rats and enhances its antitumor efficacy in HepG2 cells. Bioscience Report.2020;26: BSR20193686.